AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

RPID · NASDAQ · Medical - Devices

Rapid Micro Biosystems

Automates microbial quality-control workflows for pharmaceutical, medical-device, and personal-care manufacturing.

$1.57

After-hours close0.00 (0.00%)

At close$1.57(−2.48%)

Something off on this page? Send us feedback.

Profile

Rapid Micro Biosystems, Inc.RPIDHealth Care

Growth Direct automates microbial quality-control workflows for pharmaceutical, medical-device, and personal-care manufacturers. The platform is sold with proprietary consumables, software, and related services from a Massachusetts base.

Growth Direct is an automated microbial quality-control platform for pharmaceutical, medical-device, and personal-care manufacturing. It detects and quantifies microbial growth by combining sensitive-camera imaging with the cells’ natural autofluorescence, automating manual quality-control workflows. The company sells Growth Direct systems, proprietary consumables, LIMS-connection and other software, and related services.

Headquartered in Lexington, Massachusetts, with U.S. manufacturing in Lowell, it supports manufacturers that need microbial analysis in quality control. Operations have been funded by product and service revenue, equity financing, and borrowing, while the company has reported recurring losses and operating cash outflows since inception.

Company facts

CEORobert Spignesi

ListedJul 15, 2021

ExchangeNASDAQ

HeadquartersLexington, MA

CountryUnited States

Employees171

CIK0001380106

ISINUS75340L1044

Key statistics

Market cap$71.2M

EPS (ttm)−$1.11

P/E (ttm)−1.41

ROE-177.0%

P/B4.16

P/S2.02

Dividend yield—

Beta1.78vs XLV 0.68

Year to date −50.0% · Average volume (30d) 216.9K

Analysts

Price target, next 12 months$7.00+345.9%Median of 6 analysts · vs the Aug 28 close

ConsensusBuy4 of 6 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $1.57

High$7.00+345.9%

Median$7.00+345.9%

Low$7.00+345.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Target
May 22, 2026	Lake Street	Reiterate	Buy	$7

Earnings

EPS

Estimate−$0.19

ReportedDue Nov 6, 2026

Revenue

Estimate$10.0M

ReportedDue Nov 6, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 7, 2026Q2 FY26	−$0.24	−$0.27	−11.0%	$7.9M	$8.1M	+2.3%	−16.83%
May 13, 2026Q1 FY26	−$0.25	−$0.31	−24.0%	$7.6M	$8.0M	+5.3%	−6.45%
Mar 12, 2026Q4 FY25	−$0.23	−$0.28	−21.7%	$11.4M	$11.3M	−0.6%	−17.49%
Nov 7, 2025Q3 FY25	−$0.26	−$0.26	0.0%	$10.9M	$7.8M	−28.3%	+4.52%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$7.2M	$7.3M	$7.8M	$11.3M	$8.0M	$8.1M
Gross profit	$404.0K	$1.9M	$2.3M	−$329.0K	$371.0K	$1.2M
Operating income	−$11.7M	−$12.1M	−$11.4M	−$12.2M	−$13.9M	−$12.3M
Net income	−$11.3M	−$11.9M	−$11.5M	−$12.5M	−$14.3M	−$12.9M
Diluted EPS	−$0.26	−$0.27	−$0.25	−$0.28	−$0.31	−$0.27
Gross margin	5.6%	26.8%	29.0%	-2.9%	4.6%	15.0%
Operating margin	-161.8%	-167.3%	-145.1%	-108.2%	-173.1%	-153.0%

Fiscal years (4-quarter sums)FY21 $23.2M · FY22 $17.1M · FY23 $22.5M · FY24 $28.1M · FY25 $33.6M

Revenue by product · Q2 FY26

Product$5.4M · 66%

Service$2.8M · 34%

Revenue by geography · Q2 FY26

United States$3.0M · 37%

Switzerland$1.4M · 17%

All Other Countries$1.1M · 13%

Japan$1.0M · 13%

Germany$892.0K · 11%

Korea, Republic of$693.0K · 9%

Balance sheet, Jun 30, 2026Cash & short-term investments $19.8M · Total debt $23.5M · Total assets $58.5M · Shareholders' equity $17.7M

Dividends

No dividends on record.

Ownership

Institutions 34.95%15.84M sharesInsiders 5.50%2.49M sharesOther 59.55%26.99M shares

Shares outstanding 45.32M · Float 26.44M · 58.3% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Bain Capital Life Sciences Investors, LLC	8.43M	18.61%	13F	May 15, 2026
Longitude Capital Partners II, LLC	3.53M	8.60%	13G	May 15, 2026
Armistice Capital, LLC	3.33M	7.29%	13G	Aug 14, 2026
Endeavour Medtech Growth II LP	2.26M	5.70%	13G	Feb 13, 2026
Abg-WTT Global Life Science Capital Partners GP Ltd	1.85M	4.08%	13F	May 18, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
May 20, 2026	Bain Capital Life Sciences Investors, LLC	10 percent owner	+4,389,000	$1.44
Mar 10, 2026	Robert G. Jr. Spignesi	director, officer: PRESIDENT AND CEO	−17,922	$4.11
Mar 11, 2026	Sean M. Wirtjes	officer: CHIEF FINANCIAL OFFICER	−7,480	$4.32
Mar 11, 2026	John J. Addington Wilson	officer: CHIEF OPERATING OFFICER	−9,603	$4.32
Feb 19, 2026	Robert G. Jr. Spignesi	director, officer: PRESIDENT AND CEO	−38,327	$3.89